Arginine tango
As a means to evade the host immune response, S. aureus uses an enzyme called oleate hydratase, or OhyA, to inactivate antimicrobial unsaturated fatty acids in the membrane that would otherwise inhibit bacterial growth. Research scientists at St. Jude Children’s Research Hospital reported today the structure and catalytic mechanism of OhyA.
Christopher Radka of St. Jude’s Department of Infectious Diseases describes the research during a presentation Tuesday at 2 p.m. EDT at the 2021 ASBMB Annual Meeting, held in conjunction with the Experimental Biology conference.
Radka and colleagues used X-ray crystallography to determine the structure of OhyA. Solving and evaluating multiple OhyA crystal structures highlighted a coordinated dance that occurs between key arginine residues and the unsaturated fatty acid substrate in the active site of the enzyme, a process facilitated by the nucleotide cofactor FAD.
In this dance, the substrate is first guided into the binding tunnel by the oleate carbonyl of OhyA, then encounters its first arginine dance partner (Arg81) at the entrance of the active site. FAD binding then triggers the rotation of Arg81 that guides the fatty acid as it curls into the active site. After catalysis, a second arginine (Arg78) rotates behind the fatty acid carboxyl to release the hydroxylated product from the active site.
“What’s novel about the (active site) is how these conserved arginines guide the substrate through the donut-shaped active site,” Radka said. “Here, the arginines dance like two partners in a tango.”
This highly choreographed dance controls how the fatty acid substrate moves into and out of the active site. “In this coordinated tango at the active site, the FAD is the dramatic third character whose role is to come in and advance the dance so the chemistry can occur,” Radka said.
In this reaction, FAD remains oxidized and unconsumed. This quality is advantageous for industrial biotechnology research looking to use OhyA; FAD-dependent reactions often consume FADH2 and require continued starting product, which can be costly.
Future goals for this research include determining the structural elements required for S. aureus OhyA to remove antimicrobial fatty acids from the membrane.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Disease-linked mutations disrupt protein phase behavior
Researchers find that pathogenic missense mutations are enriched threefold in phrase-separating intrinsically disordered regions of proteins.

The dual role of asprosin in chronic fatty liver disease
Researchers uncover a hormone called asprosin that may serve as a potential biomarker for the diagnosis of chronic fatty liver disease and monitoring disease progression.

Novel inhibitor targets RAS-driven cancers
Researchers in Louisville identify a small-molecule drug that blocks RALGEF signaling downstream of mutant RAS. The compound suppresses tumor growth with low toxicity, revealing a new therapeutic strategy for RAS-driven malignancies.

Catching tau in the act
Using a new proximity-labeling approach, researchers reveal how tangles of the brain-associated protein tau may disrupt RNA biology long before neurons die.

How copper delivery fuels bacterial respiration
Researchers identify the roles of several proteins in copper homeostasis in the aerobic bacterium Caulobacter vibrioides.

Revealing the glycoproteome of a cancer subtype
Researchers mapped the glycoproteome of extrahepatic cholangiocarcinoma and compared it to intrahepatic tumors. Differences in sugar modifications and immune cell content suggest new biomarkers and guide development of targeted immunotherapies.